To understand ripening-dependent changes in phytonutrients, five commercial cultivars of red peppers (Capsicum annuum L.) grown in an open field in Taean, South Korea, were selected and their fruits were harvested at green mature (GM), intermediate breaker (BR), and red ripe (RR) stages and their phytonutrient contents and antioxidant activities were compared. Three major patterns in relation to ripening progress were observed. First, continuous increases were observed in vitamin C, total phenol, vitamin E (especially α-tocopherol), total free sugar, β-carotene, linolenic acid content, and antioxidant activity. Second, decreasing patterns were observed in phytosterols (campesterol, stigmasterol, and β-sitosterol) and linoleic acid. Third, total flavonoid and squalene contents were relatively higher at the BR stage compared with the GM and RR stages. These results indicate that each phytonutrient has a unique pattern of accumulation and degradation during the fruit-maturing process. Unlike the mentioned phytonutrients, which showed similar patterns in all tested cultivars, capsaicinoids exhibited quite different patterns of ripening-dependent changes among the cultivars. Throughout the ripening processes, positive correlations with antioxidant activity were observed in vitamin E (r = 0.814**), β-carotene (r = 0.772*), vitamin C (r = 0.610**), and total phenol (r = 0.595**) contents, whereas capsaicinoids, total flavonoid, and phytosterols exhibited no or slightly negative correlations. In conclusion, the ripening of red pepper fruits is accompanied by continuous increments in various phytonutrients and subsequent antioxidant activity.

Bioassay-guided fractionation of the H(2)O extract of the seeds of Psoralea corylifolia furnished one hepatoprotective compound, bakuchiol (1), together with two moderately active compounds, bakuchicin (2) and psoralen (3), on tacrine-induced cytotoxicity in human liver-derived Hep G2 cells. The EC(50) values of compounds 1 - 3 are 1.0, 47.0, 50.0 microg/ml, respectively. Silymarin as a positive control showed the EC(50) value with 5.0 microg/ml.

BackgroundPrevious animal studies have shown that Curcuma longa (turmeric) improves liver function. Turmeric may thus be a promising ingredient in functional foods aimed at improving liver function. The purpose of the study is to investigate the hepatoprotective effect of fermented turmeric powder (FTP) on liver function in subjects with elevated alanine transaminase (ALT) levels.MethodsA randomised, double-blind, placebo-controlled trial was conducted between November 2010 and April 2012 at the clinical trial center for functional foods of the Chonbuk National University Hospital. The trial included 60 subjects, 20 years old and above, who were diagnosed mild to moderate elevated ALT levels between 40 IU/L and 200 IU/L. Sixty subjects were randomised to receive FTP 3.0 g per day or placebo 3.0 g per day for 12 weeks. The treatment group received two capsules of FTP three times a day after meals, for 12 weeks. The primary efficacy endpoint was change in the ALT levels in the two groups. The secondary efficacy endpoints included its effect on aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), total bilirubin (TB), and lipid profiles. Safety was assessed throughout the study using ongoing laboratory tests. Adverse events (AEs) were also recorded.ResultsSixty subjects were randomised in the study (30 into the FTP group, 30 into the placebo group), and among them, twelve subjects were excluded from the analysis for protocol violation, adverse events or consent withdrawal. The two groups did not differ in baseline characteristics. After 12 weeks of treatment, 48 subjects were evaluated. Of the 48 subjects, 26 randomly received FTP capsules and 22 received placebo. The FTP group showed a significant reduction in ALT levels after 12 weeks of treatment compared with the placebo group (p = 0.019). There was also observed that the serum AST levels were significantly reduce in the FTP group than placebo group (p = 0.02). The GGT levels showed a tendency to decrease, while the serum alkaline phosphatase (ALP), TB, and lipids levels were not modified. There were no reported severe AEs during this study, or abnormalities observed on blood glucose, total protein, albumin, blood urea nitrogen (BUN), and creatinine levels.ConclusionThe data of this trial indicate that FTP is effective and safe, generally well-tolerated without severe AEs, in the treatment of subjects with elevated ALT levels over a 12 weeks period.Trial registrationClinicalTrials.gov: http://NCT01634256

No abstract

No abstract